Adding Liver-Directed Therapy to Immunotherapy Doubles Survival in Advanced Liver Cancer

For patients with the most dangerous form of liver cancer, a new study offers a glimmer of hard-won progress. Researchers in China report that combining two liver-directed techniques—transarterial chemoembolization and hepatic arterial infusion chemotherapy—with the now-standard duo of targeted drugs and immunotherapy nearly doubled median overall survival in patients with advanced hepatocellular carcinoma whose tumors have invaded the portal vein. The retrospective cohort study, published in BMC Cancer, analyzed 92 patients across two treatment centers and used propensity score matching to reduce the biases that plague comparisons of different treatments in observational data. The findings, while not from a randomized trial, add weight to a growing conviction among hepatobiliary oncologists that attacking liver tumors locally and systemically at the same time may be more powerful than either approach alone.

Hepatocellular carcinoma is the most common primary liver malignancy and a leading cause of cancer death worldwide, particularly in regions where chronic hepatitis B infection is prevalent. The disease often announces itself late, and one of its most ominous signatures is a portal vein tumor thrombus—cancer cells growing into the major vein that carries blood from the gut to the liver. In the classification system used by Chinese hepatologists, such invasion is graded Vp3 or Vp4 depending on whether the thrombus extends into the main portal vein or its contralateral branches. Patients in this category have historically faced grim prospects, because the tumor has already established a highway for spread into the rest of the liver and beyond, and because the compromised liver itself limits how much treatment a patient can tolerate.

In recent years, the backbone of treatment for advanced disease has shifted to systemic combinations: an oral tyrosine kinase inhibitor that starves tumors of their blood supply, paired with an immune checkpoint inhibitor that releases the brakes on T cells. This targeted-immunotherapy approach has improved outcomes compared with older single-agent therapies, but response rates remain modest and many patients progress within months. The question driving the new research was whether adding catheter-based liver treatments on top of these drugs could push survival further. Transarterial chemoembolization delivers chemotherapy directly into the arteries feeding the tumor and then blocks those vessels, concentrating the drug while cutting off nourishment. Hepatic arterial infusion chemotherapy, meanwhile, threads a catheter into the hepatic artery for continuous infusion of high-dose cytotoxic agents, exploiting the fact that liver tumors draw most of their blood from that artery while healthy liver tissue relies on the portal vein.

The study team, led by Qihong Chen and Zhuting Fang of Fujian Cancer Hospital with colleagues at the First Hospital of Putian and collaborating institutions, enrolled 92 patients with Vp3 or Vp4 hepatocellular carcinoma treated at the two centers. Forty-eight patients received the combination of TACE or HAIC with targeted-immunotherapy, while the remainder received targeted-immunotherapy alone. Because patients were not randomly assigned, the researchers used propensity score matching at a 1:2 ratio, a statistical technique that pairs treated and untreated patients with similar baseline characteristics—such as age, liver function, tumor burden, and performance status—to mimic the balance of a randomized experiment. After matching, 48 combination-therapy patients were compared against 31 patients on systemic therapy alone.

The results were striking on the primary measure of tumor response. The objective response rate, assessed with the modified Response Evaluation Criteria in Solid Tumors, which track the viable, contrast-enhancing portion of a tumor rather than its overall size, reached 64.58 percent in the combination group versus 22.58 percent in the systemic-therapy-only group, a difference that was highly statistically significant. In practical terms, nearly two-thirds of patients who received the liver-directed add-on saw their tumors shrink substantially, compared with fewer than a quarter of those on drugs alone. Tumor shrinkage matters not only as a statistical endpoint; in liver cancer, a meaningful reduction in tumor burden can convert an untreatable situation into one where curative-intent options such as resection or ablation become conceivable.

Survival data told a similar story. Median overall survival was 14.2 months in the combination group versus 7.7 months with targeted-immunotherapy alone, corresponding to a hazard ratio of 0.481—meaning the risk of death at any given time was roughly halved. Multivariable Cox regression, which adjusts for multiple factors simultaneously, confirmed that combination therapy was independently associated with a lower risk of death, with a hazard ratio of 0.451. Interestingly, the difference in median progression-free survival—5.8 versus 4.1 months—did not reach statistical significance, a pattern the authors suggest may reflect the relatively small sample size and the fact that progression in these patients is often driven by the biology of portal vein invasion rather than by the treated tumor mass alone.

One of the most clinically useful findings emerged from an exploratory subgroup analysis. Patients whose liver function fell into grade 2 or 3 on the albumin-bilirubin, or ALBI, score—a simple metric that combines serum albumin and bilirubin to quantify hepatic reserve—appeared to derive greater benefit from the combination approach than patients with better-preserved livers. This is somewhat counterintuitive, since a damaged liver might be expected to fare worse under the added insult of arterial chemotherapy and embolization. The authors caution that this observation requires prospective validation, but if confirmed it would help clinicians identify which patients stand to gain the most from an intensified regimen, and it challenges the assumption that only patients with pristine liver function should be offered aggressive locoregional therapy.

Safety, as always in combination oncology, is the counterweight to efficacy. The incidence of grade 3 or worse liver-related adverse events, graded according to the Common Terminology Criteria for Adverse Events, was significantly higher in the combination group—25.00 percent versus 6.45 percent. These events included elevations in liver enzymes and bilirubin, the expected consequences of deliberately injuring tumor-adjacent liver tissue. Crucially, however, all such events were reversible with supportive care, and no treatment-related deaths occurred in the study. The authors frame this as a manageable safety profile, one that demands careful patient selection and vigilant monitoring of hepatic function during treatment, but does not preclude the strategy in patients whose livers can withstand the burden.

The study’s design carries inherent limitations that temper enthusiasm. As a retrospective cohort with a modest sample size, it cannot eliminate selection bias entirely, even with propensity matching; unmeasured differences between patients who received liver-directed therapy and those who did not may persist. The heterogeneity of the regimens—some patients received TACE, others HAIC, and the targeted and immunotherapy agents varied—mirrors real-world practice but complicates interpretation. The authors themselves emphasize that randomized prospective trials are needed before the combination can be considered a standard of care. Still, the magnitude of the survival difference, the consistency of the response-rate benefit, and the corroboration from multivariable analysis make a compelling case that the question deserves definitive testing.

If larger trials confirm these results, the implications for the millions of people living with hepatitis B-related liver cancer could be substantial. The strategy is conceptually elegant: use catheter-based arterial therapies to deliver a concentrated cytotoxic blow to the tumor and its portal vein thrombus, while systemic targeted-immunotherapy patrols for micrometastatic disease and, perhaps, is potentiated by the release of tumor antigens caused by local treatment. The Fujian study adds to a small but growing body of evidence that the era of purely systemic treatment for advanced hepatocellular carcinoma may be giving way to a more integrated model, in which the interventional radiologist’s catheter and the medical oncologist’s prescriptions work in concert. For patients facing a diagnosis that once carried a prognosis measured in months, that convergence may soon translate into years.

Subject of Research: Combining transarterial therapies with targeted-immunotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus

Article Title: Efficacy and safety of TACE/HAIC combined with targeted-immunotherapy versus targeted-immunotherapy alone in Vp3-4 hepatocellular carcinoma: a propensity score-matched retrospective cohort study based on two-center data

Article References: Efficacy and safety of TACE/HAIC combined with targeted-immunotherapy versus targeted-immunotherapy alone in Vp3-4 hepatocellular carcinoma: a propensity score-matched retrospective cohort study based on two-center data. (n.d.). https://doi.org/10.1186/s12885-026-17061-4

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17061-4

Keywords: hepatocellular carcinoma, portal vein tumor thrombus, TACE, HAIC, targeted-immunotherapy, overall survival, propensity score matching, liver cancer, combination therapy, adverse events, ALBI grade, BMC Cancer